“…In general, supramolecular biomaterials show a relative ease of processing and provide the possibility to finely tune the morphological, chemical, and thereby, degradation properties (Bouten et al, 2011; Brugmans et al, 2015; van Almen et al, 2016). Accordingly, these materials are being tested with regard to in situ tissue engineering for cardiovascular applications (Muylaert et al, 2015; van Almen et al, 2016; Bockeria et al, 2017; Kluin et al, 2017; Bennink et al, 2018). PCL-BU scaffolds, specifically, have been tested as vascular grafts, revealing relatively rapid degradation kinetics in vivo (Duijvelshoff et al, 2018).…”